SINGAPORE, May 22 Edwards LifesciencesCorporation (NYSE: EW), the world leader in the science of heart valves, todayannounced the opening of its new heart valve manufacturing facility in ChangiNorth Crescent, Singapore. The state-of-the-art facility produces Edwards'world-leading Carpentier-Edwards PERIMOUNT tissue heart valve replacements,and also serves as the headquarters for Edwards' Asia-Pacific operations, oneof the company's fastest-growing regions.
"Edwards' new Singapore facility was developed to meet the global demandsfor our technologically advanced tissue heart valve replacement products,"said Donald E. Bobo, Jr., Edwards' corporate vice president, heart valvetherapy. "The opening coincides with our 50th anniversary of partnering withclinicians to develop life-saving innovations and we look forward to servingmore patients around the world through our heart valve operations in theUnited States, Switzerland, and now, Singapore."
About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valvesand hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards treatsadvanced cardiovascular disease with its market-leading heart valve therapies,and critical care and vascular technologies. In 2008, Edwards celebrates 50years of partnering with clinicians to develop life-saving innovations. Thecompany's global brands, which are sold in approximately 100 countries,include CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty,PERIMOUNT Magna and Swan-Ganz. Additional company information can be found athttp://www.edwards.com
Edwards is a trademark of Edwards Lifesciences Corporation. EdwardsLifesciences, the stylized E logo, CardioVations, Carpentier-Edwards,Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT, PERIMOUNT Magna and Swan-Ganzare trademarks of Edwards Lifesciences Corporation and are registered in theUnited States Patent and Trademark Office.
SOURCE Edwards Lifesciences Corporation